Related Experiment Video
Updated: Jun 26, 2026
09:49
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
ABL1 fusions in T-cell acute lymphoblastic leukemia
1Center for Human Genetics, Katholieke Universiteit Leuven, VIB Department of Molecular and Developmental Genetics, Campus Gasthuisberg O&N1 box 602, Herestraat 49, B-3000 Leuven.
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie
|January 27, 2009
Summary
Fusion tyrosine kinases drive T-cell acute lymphoblastic leukemia (T-ALL). NUP214-ABL1 and EML1-ABL1 are activated via distinct mechanisms, offering new therapeutic targets. Kinase mutations appear late, suggesting combination therapies are crucial for T-ALL treatment.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Mutant tyrosine kinases are prevalent drivers in various cancers, making them key therapeutic targets.
- T-cell acute lymphoblastic leukemia (T-ALL) pathogenesis involves activated kinases, including fusion genes like NUP214-ABL1.
Purpose of the Study:
- To investigate the role and activation mechanisms of NUP214-ABL1 and EML1-ABL1 fusion genes in T-ALL.
- To explore the therapeutic potential of targeting these fusion kinases and their cooperation with other mutations in T-ALL.
Main Methods:
- Studied NUP214-ABL1 and EML1-ABL1 fusion genes in T-ALL patient samples and established mouse models.
- Assessed kinase activity, cellular localization, and transformation potential of fusion proteins.
- Investigated the timing of kinase mutations in T-ALL development and evaluated combination therapies.
Main Results:
- NUP214-ABL1 and EML1-ABL1 exhibit constitutive kinase activity and are sensitive to imatinib.
- EML1-ABL1 activation depends on coiled-coil domain homo-oligomerization, while NUP214-ABL1 activation relies on nuclear pore complex localization.
- Tyrosine kinase mutations were found to occur late in T-ALL development.
- In vitro studies showed synergistic effects between NUP214-ABL1 and NOTCH1 inhibition.
Conclusions:
- NUP214-ABL1 activation via nuclear pore complex localization represents a novel oncogenic mechanism.
- Targeting ABL1 fusion proteins, potentially in combination with other therapies like NOTCH1 inhibition, shows promise for T-ALL treatment.
- Development of multi-mutation T-ALL models is essential for validating combination therapies and understanding T-ALL genesis.
